In vitro binding of [³H]PIB to human amyloid deposits of different types

References

• Guan J, Mishra S, Falk R, Liao R. Current perspectives on cardiac amyloidosis. Am J Physiol Heart Circ Physiol 2012;302:H544–52
   PubMed Web of Science ®Google Scholar
• Picken MM. New insights into systemic amyloidosis: the importance of diagnosis of specific type. Curr Opin Hypertens 2007;16:196–293
   PubMed Web of Science ®Google Scholar
• Merlini G, Seldin D, Gertz MA. Amyloidosis: pathogenesis and new therapeutic options. J Clin Oncol 2011;29:1924–33
   PubMed Web of Science ®Google Scholar
• Westermark P, Benson MD, Buxbaum JN, Cohen AS, Frangione B, Ikeda S, Masters CL, et al. A primer of amyloid nomenclature. Amyloid 2007;14:179–83
   PubMed Web of Science ®Google Scholar
• Sipe JD, Benson MD, Buxbaum JN, Ikeda SI, Merlini G, Saraiva MJM, Westermark P. Amyloid fibril protein nomenclature: 2012 recommendations from the Nomenclature Committee of the International Society of Amyloidosis. Amyloid 2012;19:167–70
   PubMed Web of Science ®Google Scholar
• Dispenzieri A, Gertz MA, Buadi F. What do I need to know about immunoglobulin light chain (AL) amyloidosis? Blood Reviews 2012;26:137–54
   PubMed Web of Science ®Google Scholar
• Picken MM. Amyloidosis – Where are we now and where are we heading? Arch Pathol Lab Med 2010;134:545–51
   PubMed Web of Science ®Google Scholar
• Westermark P. Amyloid diagnosis, subcutaneous adipose tissue, immunohistochemistry and mass spectrometry. Amyloid 2011;18:175–6
   PubMed Web of Science ®Google Scholar
• Lavatelli F, Vrana JA. Proteomic typing of amyloid deposits in systemic amyloidosis. Amyloid 2011;18:177–82
   PubMed Web of Science ®Google Scholar
• Hawkins PN, Lavender JP, Pepys MB. Evaluation of systemic amyloidosis by scintigraphy with 123I-labeled serum amyloid P component. N Engl J Med 1990;323:508–13
   PubMed Web of Science ®Google Scholar
• Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med 2003;349:583–96
   PubMed Web of Science ®Google Scholar
• Pepys MB, Booth DR, Hutchinson WL, Gallimore JR, Collins PM, Hohenester E. Amyloid P component: a critical review. Amyloid 1997;4:274–95
   Web of Science ®Google Scholar
• Hazenberg BP, van Rijswijk MH, Piers DA, Lub-de Hooge MN, Vellanga E, Haagsma EB, Hawkins PN, et al. Diagnostic performance of 123I-labeled serum amyloid P component scintigraphy in patients with amyloidosis. Am J Med 2006;119:e15–24
   Google Scholar
• Wall JS, Richey T, Stuckey A, Donnell R, Macy S, Martin EB, Williams A, et al. In vivo molecular imaging of peripheral amyloidosis using heparin-binding peptides. Proc Natl Acad Sci USA 2011;108:E586–94
   Web of Science ®Google Scholar
• Wall JS, Richey T, Macy S, Heidel E, Wooliver C, Kennel SJ. A novel method for quantifying peripheral tissue amyloid load by using the radiolabeled amyloidophilic peptide, p5. Amyloid 2013;20:21–6
   Web of Science ®Google Scholar
• LeVine H 3rd. Quantification of beta-sheet amyloid fibril structures with thioflavin T. Methods Enzymol 1999;309:274–84
   PubMed Web of Science ®Google Scholar
• Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, Bergström M, et al. Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound B. Ann Neurol 2004;55:306–19
   PubMed Web of Science ®Google Scholar
• Engler H, Forsberg A, Almkvist O, Blomquist G, Larsson E, Savitcheva I, Wall A, et al. Two-year follow-up of amyloid deposition in patients with Alzheimer’s disease. Brain 2006;129:2856–66
   PubMed Web of Science ®Google Scholar
• Bacskai BJ, Frosch MP, Freeman SH, Raymond SB, Augustinack JC, Johnson KA, Irizarry MC, et al. Molecular imaging with Pittsburgh Compound B confirmed at autopsy. A case report. Arch Neurol 2007;64:431–4
   PubMed Web of Science ®Google Scholar
• Ikonomovic MD, Klunk WE, Abrahamson EE, Mathis CA, Price JC, Tsopelas ND, Lopresti BJ, et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain 2008;131:1630–45
   PubMed Web of Science ®Google Scholar
• Kadir A, Marutle A, Gonzales D, Schöll M, Almkvist O, Mousavi M, Mustafiz T, et al. Positron emission tomography imaging and clinical progression in relation to molecular pathology in the first Pittsburgh Compound B position emission tomography patient with Alzheimer’s disease. Brain 2011;134:301–17
   PubMed Web of Science ®Google Scholar
• Klunk WE, Lopresti BJ, Ikonomovic MD, Lefterov IM, Koldamova RP, Abrahamson EE, Debnath ML, et al. Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer's disease brain but not in transgenic mouse brain. J Neurosci 2005;25:10598–606
   PubMed Web of Science ®Google Scholar
• Bergström J, Murphy CL, Weiss DT, Solomon A, Sletten K, Hellman U, Westermark P. Two different types of amyloid deposits-apolipoprotein A-IV and transthyretin-in a patient with systemic amyloidosis. Lab Invest 2004;84:981–8
   PubMed Web of Science ®Google Scholar
• Westermark P, Davey E, Lindbom K, Enqvist S. Subcutaneous fat tissue for diagnosis and studies of systemic amyloidosis. Acta Histochem 2006;108:209–13
   PubMed Web of Science ®Google Scholar
• Masters CL, Simms G, Weinman NA, Multhau G, McDonald BL, Beyreuther K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci USA 1985;82:4245–9
   PubMed Web of Science ®Google Scholar
• Fodero-Tavoletti MT, Smith DP, McLean CA, Adlard PA, Barnham KJ, Foster LE, Leone L, et al. In vitro characterization of Pittsburgh Compound-B binding to Lewy bodies. J Neurosci 2007;27:10365–71
   PubMed Web of Science ®Google Scholar
• Westermark G, Sletten K, Grubb A, Westermark P. AA-amyloidosis. Tissue component-specific association of various protein A subspecies and evidence of a fourth SAA gene product. Am J Pathol 1990;137:377–83
   PubMed Web of Science ®Google Scholar
• Husby G, Stenstad T, Magnus JH, Sletten K, Nordvåg BY, Marhaug G. Interaction between circulating amyloid fibril precursors and extracellular tissue matrix components in the pathogenesis of systemic amyloidosis. Clin Immunol Immunopathol 1994;70:2–9
   PubMedGoogle Scholar
• Leone O, Longhi S, Quarta CC, Ragazzini T, Badiali De Giorgi L, Pasquale F, Potena L, et al. New pathological insights into cardiac amyloidosis: implications for non-invasive diagnosis. Amyloid 2012;19:99–105
   PubMed Web of Science ®Google Scholar
• Hellström-Lindahl E, Ravid R, Nordberg A. Age-dependent decline of neprilysin in Alzheimer’s disease and normal brain: inverse correlation with Aβ levels. Neurobiol Aging 2008;29:210–21
   PubMed Web of Science ®Google Scholar
• Hellstrom-Lindahl E, Vitanen M, Marutle A. Comparison of Aβ levels in the brain of Swedish APP670, 671 and PS1M146V mutation carriers and patients with sporadic Alzheimer’s disease. Neurochem Int 2009;55:243–52
   Google Scholar
• Svedberg MM, Hall H, Hellström-Lindahl E, Estrada S, Guan Z, Nordberg A, Långström B. [11C]PIB-amyloid binding and levels of Abeta40 and Abeta42 in postmortem brain tissue from Alzheimer patients. Neurochem Int 2009;54:347–57
   PubMed Web of Science ®Google Scholar
• Kaplan B, Shtrasburg S, Pras M. Micropurification techniques in the analysis of amyloid proteins. J Clin Pathol 2003;56:86–90
   Google Scholar
• Delacourte A, Sergeant N, Champain D, Wattez A, Maurage CA, Lebert F, Pasquier F, et al. Nonoverlapping but synergetic tau and APP pathologies in sporadic Alzheimer’s disease. Neurology 2002;59:398–407
   PubMed Web of Science ®Google Scholar
• Youmans KL, Leung S, Zhang J, Maus E, Baysac K, Bu G, Vassar R, et al. Amyloid-β42 alters apolipoprotein E solubility in brains of mice with five familial AD mutations. J Neurosci Methods 2011;196:51–9
   Google Scholar
• Antoni G, Lubberink M, Estrada S, Axelsson J, Carlsson K, Lindsjö L, Långström B, et al. In vivo visualization of amyloid deposits in the heart with [11C]PIB and PET. J Nucl Med 2013;54:213–20
   PubMed Web of Science ®Google Scholar